The Food and Drug Administration approved an immunotherapy drug for tumors with high tumor mutational burden regardless of tumor type. But some medical oncologists say it's not clear the biomarker is valid across all cancer types.

by Anna Azvolinsky

From the Editor-in-Chief

Paying attention to the social determinants of health will promote greater equity in cancer outcomes for all.

by William G. Nelson, MD, PhD

Patient advocates with metastatic breast cancer argue that dosing of treatments for their disease should be more personalized and take into account quality of life.

by Marcus A. Banks

Advances in precision medicine and immunotherapy have led to better treatments for many patients with advanced lung cancer. But having a wider selection of therapies to choose from can make treatments more complex.

by Kendall K. Morgan

Forward Look

The Clinical Treatment Act aims to include more Medicaid recipients.

by Jen Tota McGivney

Healthy Habits

Awareness of the link between cancer risk and a diet lacking fruits and vegetables has been declining.

by Carisa D. Brewster

Forward Look

Fear of discrimination may lead to lower screening rates.

by Tara Santora

Forward Look

A therapeutic vaccine targeting advanced cervical cancer.

by Anna Azvolinsky

A trial of the targeted therapy Tagrisso (osimertinib) for early-stage lung cancer finds that patients who take it go longer without having a cancer recurrence. Whether that should change clinical practice is under discussion.

by Ashley P. Taylor

Neoadjuvant therapy—using treatments such as chemotherapy, hormone therapy or radiation to shrink a tumor or treat unseen metastases before surgery—can improve outcomes for some patients.

by Sharon Tregaskis